As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D
and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver
groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include
chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing
and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization),
helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi
AppTec received AA ESG rating from MSCI in 2021 and its open access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease
can be treated." Please visit: http://www.wuxiapptec.com.
